32,135 Shares in Becton, Dickinson and Company $BDX Acquired by Core Capital Management & Research inc.

Core Capital Management & Research inc. bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 32,135 shares of the medical instruments supplier's stock, valued at approximately $4,863,000. Becton, Dickinson and Company accounts for 2.6% of Core Capital Management & Research inc.'s investment portfolio, making the stock its 12th biggest position.

Other institutional investors and hedge funds have also modified their holdings of the company. Imprint Wealth LLC bought a new position in Becton, Dickinson and Company in the 3rd quarter worth $25,000. SHP Wealth Management bought a new stake in Becton, Dickinson and Company during the fourth quarter valued at about $26,000. Meeder Asset Management Inc. grew its position in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock valued at $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $29,000. Finally, Bell Investment Advisors Inc bought a new position in shares of Becton, Dickinson and Company in the second quarter worth about $29,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares of the company's stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares of the company's stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 8,005 shares of company stock worth $1,423,580. Insiders own 0.40% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Evercore set a $180.00 target price on Becton, Dickinson and Company in a report on Monday, July 6th. Piper Sandler increased their price objective on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Friday, August 7th. The Goldman Sachs Group lowered their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 27th. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $187.67.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $179.92 on Thursday. The firm has a market capitalization of $49.57 billion, a PE ratio of 54.19, a PEG ratio of 12.62 and a beta of 0.21. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $193.07. The business's 50 day moving average is $171.75 and its 200-day moving average is $160.59.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm had revenue of $4.98 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same period last year, the business earned $3.68 earnings per share. Becton, Dickinson and Company's quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD's products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.